Haanen, John B.

Acquired and intrinsic resistance in cancer immunotherapy

Kelderman, S., Schumacher, T. N. M., & Haanen, J. B. A. G. (2014) · Molecular Oncology

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 197

Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors

de Moel, E. C., Rozeman, E. A., Kapiteijn, E. H., Verdegaal, E. M. E., Grummels, A., Bakker, J. A., Huizinga, T. W. J., Haanen, J. B., Toes, R. E. M., & van der Woude, D. (2019) · Cancer Immunology Research

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 191

Fixed Dosing of Monoclonal Antibodies in Oncology

Hendrikx, J. J. M. A., Haanen, J. B. A. G., Voest, E. E., Schellens, J. H. M., Huitema, A. D. R., & Beijnen, J. H. (2017) · The Oncologist

Monoclonal and Polyclonal Antibodies ResearchPharmaceutical studies and practices

Cited by 168

Cryoablation and immunotherapy: an overview of evidence on its synergy

Aarts, B. M., Klompenhouwer, E. G., Rice, S. L., Imani, F., Baetens, T., Bex, A., Horenblas, S., Kok, M., Haanen, J. B. A. G., Beets-Tan, R. G. H., et al. (2019) · Insights into Imaging

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 152

Serous Retinopathy Associated with Mitogen-Activated Protein Kinase Kinase Inhibition (Binimetinib) for Metastatic Cutaneous and Uveal Melanoma

van Dijk, E. H. C., van Herpen, C. M. L., Marinkovic, M., Haanen, J. B. A. G., Amundson, D., Luyten, G. P. M., Jager, M. J., Kapiteijn, E. H. W., Keunen, J. E. E., Adamus, G., et al. (2015) · Ophthalmology

Drug-Induced Ocular ToxicityOcular Oncology and Treatments

Cited by 79

Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor–Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial

Rini, B. I., Moslehi, J. J., Bonaca, M., Schmidinger, M., Albiges, L., Choueiri, T. K., Motzer, R. J., Atkins, M. B., Haanen, J., Mariani, M., et al. (2022) · Journal of Clinical Oncology

Renal cell carcinoma treatmentChemotherapy-induced cardiotoxicity and mitigation

Cited by 77

Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse events

Hoefsmit, E. P., Rozeman, E. A., Haanen, J. B. A. G., & Blank, C. U. (2019) · ESMO Open

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 29

LBA38 BNT211-01: A Phase I Trial to Evaluate Safety and Efficacy of CLDN6 CAR T Cells and CLDN6-Encoding MRNA Vaccine-Mediated in Vivo Expansion in Patients with CLDN6-Positive Advanced Solid Tumours

Mackensen, A., Haanen, J. B. A. G., Koenecke, C., Alsdorf, W., Wagner-Drouet, E., Heudobler, D., Borchmann, P., Bokemeyer, C., Klobuch, S., Smit, E., et al. (2022) · Annals of Oncology

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 25

Belzutifan (bel) plus lenvatinib (lenva) versus cabozantinib (cabo) for advanced renal cell carcinoma (RCC) after anti–PD-(L)1 therapy: Open-label phase 3 LITESPARK-011 study.

Motzer, R. J., Park, S. H., McDermott, R. S., Porta, C., Heng, D. Y. C., Burotto, M., Iacovelli, R., Verzoni, E., Cutuli, H., Haanen, J., et al. (2026) · Journal of Clinical Oncology

Renal cell carcinoma treatmentCancer Immunotherapy and Biomarkers

Cited by 9